DK0832093T3 - Udtrykkelse af lipoproteiner - Google Patents

Udtrykkelse af lipoproteiner

Info

Publication number
DK0832093T3
DK0832093T3 DK96918793T DK96918793T DK0832093T3 DK 0832093 T3 DK0832093 T3 DK 0832093T3 DK 96918793 T DK96918793 T DK 96918793T DK 96918793 T DK96918793 T DK 96918793T DK 0832093 T3 DK0832093 T3 DK 0832093T3
Authority
DK
Denmark
Prior art keywords
protein
lipidated
disclosed
leader sequence
heterologous
Prior art date
Application number
DK96918793T
Other languages
Danish (da)
English (en)
Inventor
Maryanne B Gray
Robert C Huebner
Lorne F Erdile
Donald J Warakomski
Robert S Becker
Derek L Pyle
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Application granted granted Critical
Publication of DK0832093T3 publication Critical patent/DK0832093T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK96918793T 1995-06-07 1996-06-05 Udtrykkelse af lipoproteiner DK0832093T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47578195A 1995-06-07 1995-06-07
US48637395A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
DK0832093T3 true DK0832093T3 (da) 2007-01-08

Family

ID=27044930

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96918793T DK0832093T3 (da) 1995-06-07 1996-06-05 Udtrykkelse af lipoproteiner

Country Status (13)

Country Link
EP (2) EP0832093B1 (pt)
JP (1) JP4091112B2 (pt)
AT (1) ATE339436T1 (pt)
AU (1) AU721954B2 (pt)
CA (2) CA2704354A1 (pt)
DE (1) DE69636544T2 (pt)
DK (1) DK0832093T3 (pt)
ES (1) ES2271954T3 (pt)
FI (1) FI974422A (pt)
IL (1) IL118578A (pt)
NO (2) NO324089B1 (pt)
PT (1) PT832093E (pt)
WO (1) WO1996040718A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
ZA964896B (en) * 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
AU2003204215B2 (en) * 1998-02-03 2007-01-11 Aventis Pasteur Recombinant Lipidated PsaA Protein, Methods of Preparation and Use
US7635486B1 (en) * 1998-02-03 2009-12-22 The United States Of America As Represented By The Department Of Health And Human Services Recombinant lipidated PsaA protein, methods of preparation and use
CN100473663C (zh) * 2000-02-28 2009-04-01 启龙股份公司 奈瑟球菌蛋白质的异源表达
ES2298249T3 (es) 2000-08-18 2008-05-16 Research Foundation Of State University Of New York Ospa modificada de borrelia burgdorferi.
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP2314314A3 (en) 2004-10-25 2011-05-11 Statens Serum Institut Chlamydia trachomatis antigens for vaccine and diagnostic use
CN102836425B (zh) 2005-06-23 2015-08-19 国家血清研究中心 包含潜伏感染阶段期间所表达的抗原的结核疫苗
CA2635907C (en) 2006-01-19 2016-10-04 Mary Kay, Inc. Compositions comprising kakadu plum extract or acai berry extract
US20090324638A1 (en) * 2006-06-12 2009-12-31 Biopeptides Corp. Live bacterial vaccine
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP2199303B1 (de) 2008-12-12 2013-06-05 Euroimmun Medizinische Labordiagnostika AG Polypeptide und Verfahren zur spezifischen Detektion von Antikörpern bei Patienten mit einer Borrelieninfektion
CN102413837B (zh) 2009-04-24 2015-11-25 国立血清研究所 预防再激活的结核病tb疫苗
BR112012004451A2 (pt) 2009-08-28 2016-03-22 Mary Kay Inc formulações para o cuidado com a pele"
RU2580620C2 (ru) 2010-08-23 2016-04-10 ВАЙЕТ ЭлЭлСи СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086
PE20140173A1 (es) 2010-09-10 2014-02-20 Wyeth Llc Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624926A (en) * 1981-01-02 1986-11-25 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
CA2032914A1 (en) * 1989-12-26 1991-06-27 Peter C.K. Lau Use of bacterial lipoprotein amino terminus in fusion plasmids for in vivo expression of lipid modified polypeptides
WO1992000055A1 (en) * 1990-06-15 1992-01-09 Yale University Compositions and methods for the prevention and diagnosis of lyme disease
ATE168132T1 (de) * 1991-02-15 1998-07-15 Uab Research Foundation Strukturgen von pneumokokken-protein
AU2903892A (en) * 1991-10-22 1993-05-21 Symbicom Aktiebolag Improvement in (borrelia burgdorferi) diagnosis and prophylaxis
AU5958594A (en) * 1992-12-24 1994-07-19 Med Immune, Inc. Method of protection against (streptococcus pneumoniae) with transformed mycobacteria

Also Published As

Publication number Publication date
NO324089B1 (no) 2007-08-13
JPH11514841A (ja) 1999-12-21
CA2223300A1 (en) 1996-12-19
EP0832093A4 (en) 2001-01-03
EP1741718A3 (en) 2007-03-28
FI974422A (fi) 1998-02-04
DE69636544T2 (de) 2007-06-06
WO1996040718A1 (en) 1996-12-19
ATE339436T1 (de) 2006-10-15
IL118578A (en) 2006-12-31
AU721954B2 (en) 2000-07-20
FI974422A0 (fi) 1997-12-05
DE69636544D1 (de) 2006-10-26
CA2223300C (en) 2010-07-27
NO975619D0 (no) 1997-12-04
EP0832093A1 (en) 1998-04-01
EP1741718A2 (en) 2007-01-10
ES2271954T3 (es) 2007-04-16
CA2704354A1 (en) 1996-12-19
JP4091112B2 (ja) 2008-05-28
AU6134396A (en) 1996-12-30
PT832093E (pt) 2006-12-29
EP0832093B1 (en) 2006-09-13
IL118578A0 (en) 1996-10-16
NO975619L (no) 1998-01-30
NO20064621L (no) 1998-01-30

Similar Documents

Publication Publication Date Title
NO20064621L (no) Ekspresjon av lipoproteiner.
NO20004218L (no) Íkning av den sirkulerende halveringstiden til et antistoff- basert fusjonsprotein
NL1007028A1 (nl) Stabilisatorcombinatie.
FR2703239B1 (fr) Agrafe pour prothèse inter-épineuse.
DK0954588T3 (da) OB fusionsprotein-sammensætninger og fremgangsmåder
DE69925400D1 (de) Lasersystem-Steuerung
FI944226A0 (fi) Menetelmä tietovirtojen yhdistämiseksi
DE69735926D1 (de) Interleukin-18 Rezeptorproteine
DE69732822D1 (de) Lichtstrahl-Steuerungssystem
DE69708120D1 (de) Laser-absorbierende, lichtbleichbare zusammensetzungen
EP0608120A3 (en) Flow control device for capillary electrophoresis.
FR2702361B1 (fr) Fixateur pour les ostéosynthèses lombo-sacrées.
DE69528180D1 (de) Modifiziertes molkeprotein
IT1307309B1 (it) Peptidi stabilizzanti, polipeptidi ed anticorpi che li comprendono.
DE19681312T1 (de) Datenverbindungs-Steuerverfahren
FR2710021B1 (fr) Selle perfectionnée.
SE9003374D0 (sv) A collagen binding protein as well as its preparation
FR2701833B1 (fr) Fixateur pour les ostéosynthèses lombo-sacrées.
ATE301713T1 (de) Plazentaprotein 13
TR27243A (tr) Antimikrobiyal proteinler.
DK1342729T3 (da) Antistoffer og antisense-molekyler for G-koblet receptor der udviser selektiv affinitet for ATP
ITRM930616A0 (it) Dispositivo perfezionato per il controllo di saldatura.
EP0918796A4 (en) MONOCLONAL ANTIBODIES FOR AGGLUTINATING E. COLI HAVING A CS4-CFA / I FAMILY PROTEIN
DE59701374D1 (de) Kontrollsystem für zwei einander dicht zugeordnete, voneinander lösbare teile
FI970906A (fi) Säätelymenetelmä